EUVIMEDEUVIMED entdecken
Open Access

Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML

Warren Fiskus iD, Christopher P Mill iD, Prithviraj Bose iD, Lucia Masarova iD, Naveen Pemmaraju iD, Andrew Dunbar, Christine E Birdwell, John A Davis, Kaberi Das iD, Hanxi Hou iD, Taghi Manshouri, Antrix Jain iD und 11 weitere

Blood · 2025

DOI: 10.1182/blood.2024026388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2025. Verfasst von Warren Fiskus und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myeloproliferative Disorders, Cyclin-Dependent Kinases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rising blast percentage or secondary acute myeloid leukemia (sAML) transformation in myeloproliferative neoplasms (MPNs) leads to JAK1/2 inhibitor (JAKi) therapy resistance and poor survival. Here, we demonstrate that treatment with the CDK7 inhibitor (CDK7i) SY-5609 depletes phenotypically characterized post-MPN sAML stem/progenitor cells. In cultured post-MPN sAML SET2, HEL and patient-derived (PD) post-MPN sAML cells, SY-5609 treatment inhibited growth and induced lethality while sparing normal cells. RNA-sequencing analysis after SY-5609 treatment reduced mRNA expression of MYC, MYB, CDK4/6, PIM1, and CCND1 but increased expression of CDKN1A and BCL2L1. Mass spectrometry of SY-5609–treated MPN-sAML cells also reduced c-Myc, c-Myb, PIM1, and CDK4/6 but increased p21, caspase-9, and BAD protein levels. CRISPR-mediated CDK7 depletion also reduced cell viability of HEL cells. Cytometry by time of flight (CyTOF) analysis of SY-5609–treated PD post-MPN sAML stem/progenitor cells showed reduced c-Myc, CDK6, and PU.1 but increased protein levels of CD11b, p21, and cleaved caspase-3. Cotreatment with SY-5609 and ruxolitinib was synergistically lethal in HEL, SET2, and PD post-MPN sAML cells. A CRISPR screen in sAML cells revealed BRD4, CBP, and p300 as codependencies with CDK7i. Accordingly, cotreatment with SY-5609 and the bromodomain and extra-terminal protein inhibitor (BETi) OTX015 or pelabresib or the CBP/p300 inhibitor GNE-049 was synergistically lethal in MPN-sAML cells (including those exhibiting TP53 loss). Finally, in the HEL-Luc/GFP xenograft model, compared with each agent alone, cotreatment with SY-5609 and OTX015 reduced sAML burden and improved survival without host toxicity. These findings demonstrate promising preclinical activity of CDK7i-based combinations with BETi or CBP/p300 inhibitor against advanced MPNs, including post-MPN sAML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMyeloproliferative DisordersCyclin-Dependent KinasesProtein Kinase InhibitorsCell Transformation, NeoplasticAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsMiceCyclin-Dependent Kinase-Activating KinasePyrazolesNitrilesXenograft Model Antitumor AssaysCell Line, TumorPyrimidines

Substanzen

Cyclin-Dependent Kinase-Activating KinaseCyclin-Dependent KinasesProtein Kinase InhibitorsPyrazolesCDK7 protein, humanNitrilesruxolitinibPyrimidines

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX.
  • Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Warren Fiskus, Christopher P Mill, Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Kaberi Das, Hanxi Hou, Antrix Jain, Anna Malovannaya, Lauren B Flores, Sanam Loghavi, Courtney DiNardo

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NICHD NIH HHS

Zitieren

APA

Fiskus, W., Mill, C. P., Bose, P., Masarova, L., Pemmaraju, N., Dunbar, A., Birdwell, C. E., Davis, J. A., Das, K., Hou, H., Manshouri, T., Jain, A., Malovannaya, A., Philip, K., Alhamadani, N., Matthews, A., Lin, K., Flores, L. B., Loghavi, S., …, & Bhalla, K. N. (2025). Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML. Blood. https://doi.org/10.1182/blood.2024026388

Vancouver

Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, et al. Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2025. doi:10.1182/blood.2024026388

BibTeX
@article{Fiskus2025,
  author = {Fiskus, Warren and Mill, Christopher P and Bose, Prithviraj and Masarova, Lucia and Pemmaraju, Naveen and Dunbar, Andrew and Birdwell, Christine E and Davis, John A and Das, Kaberi and Hou, Hanxi and Manshouri, Taghi and Jain, Antrix and Malovannaya, Anna and Philip, Kevin and Alhamadani, Noor and Matthews, Alicia and Lin, Katie and Flores, Lauren B and Loghavi, Sanam and DiNardo, Courtney and Su, Xiaoping and Rampal, Raajit K and Bhalla, Kapil N},
  title = {Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML},
  journal = {Blood},
  year = {2025},
  doi = {10.1182/blood.2024026388}
}
Kostenlos starten →